Objective To investigate the incidence and treatment of bone loss in rheumatic patients treated with glucocorticoid in China. Methods From November 1, 2012 to January 31, 2013, 3136 cases of rheumatic disease who had been or were taking glucocorticoid from 46 rheumatology centers nationwide were included and their clinical data, medications, as well as bone mass were investigated. Results (1) RA (1069 cases) and SLE ( 983 cases) patients accounted for the majority . Osteopenia or osteoporosis was observed in 90% of the 3136 patients, and 41. 4% patients were found to be osteoporotic. Nearly half of patients ( 44. 7% ) with a dosage of glucocorticosteroid ( equivalent to prednisone ) >7. 5 mg/d. Even those with a daily dose of glucocorticosteroid (equivalent to prednisone) ≤2. 5 mg, 58. 5% were reported to be osteoporotic. (2) There were increased risk of osteoporosis and fracture with age. In patients younger than 30 years of age, 74. 4% were reported of bone mass reduction or osteoporosis. (3) The incidence of abnormal bone mineral density in women were higher than that in men. The mean age at menopause was lower than that the average (45. 8 years) . (4) Most patients were not giv-en adequate treatment. Prophylactic anti-osteopontin therapy was never given in 32. 7% of patients, nor did 35. 6%of patients with T score <-2. 5 received prophylactic anti-osteoporosis treatment. The mostly used treatment were calcium and vitamin D, 20. 9% received calcium alone, only 4% received bisphosphonates. Conclusion The in-cidence of bone mass reduction or osteoporosis in Chinese rheumatic patients is high while most patients are not giv-en adequate treatment.